A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma	pancreatic ductal adenocarcinoma	Active, not recruiting	Phase 1	2026-08-14		NCT05846516

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Boehringer Ingelheim	158

21 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Asklepios Kliniken Hamburg GmbH	Hamburg	Germany	1
Centre Hospitalier Universitaire Vaudois (CHUV)	Lausanne	Switzerland	7
Clara Campal Comprehesive Cancer Center	Madrid	Spain	1
Hopitaux Universitaires de Geneve (HUG)	Geneva	Switzerland	1
Hospital General Universitario Gregorio Marañón	Madrid	Spain	40
Hospital Universitari Vall d'Hebron	Barcelona	Spain	200
Hospital Universitario Fundacion Jimenez Diaz	Madrid	Spain	63
Hospital Universitario Reina Sofía	Córdoba	Spain	29
Karmanos Cancer Institute	Detroit	United States	153
Orlando Health Cancer Institute	Orlando	United States	97
Perlmutter Cancer Center at NYU Langone Hospital - Long Island	New York	United States	2
START South Texas Accelerated Research Therapeutics, LLC	San Antonio	United States	1
The University of Texas MD Anderson Cancer Center	Houston	United States	207
University Hospital Bern	Bern	Switzerland	16
University Hospitals Cleveland Medical Center	Cleveland	United States	234
University of California Los Angeles	Santa Monica	United States	11
University of Colorado Cancer Center	Aurora	United States	63
University of Florida	Gainesville	United States	144
University of Southern California	Los Angeles	United States	110
Virginia Cancer Specialists, PC	Fairfax	United States	35
Virginia Mason Medical Center	Seattle	United States	111

Clinical trials